Article
Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects.
Hepatology international - 1 Jul 2017
Ding Yanhua, Zhang Hong, Li Xiaojiao, Li Cuiyun, Chen Guiling, Chen Hong, Wu Min, Niu Junqi
Abstract excerpt
BACKGROUND: Pradefovir is efficiently converted to adefovir [9-(2-phosphonylmethoxyethyl) adenine (PMEA)], producing high hepatic PMEA concentration but low levels in the systemic circulation and kidney. The aim of this study is to evaluate the tolerability, adverse effect (AEs), pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir. METHODS: Fifty healthy subjects were divided into five...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.